Glenmark Pharmaceuticals Limited — Board Meeting, 23-05-2025: Outcome of Board Meeting

Glenmark Pharmaceuticals has announced a board meeting on May 23, 2025, approving the financial results for the year. The company posted consolidated revenue of ₹9,287.56 Cr but reported a net loss of ₹277.75 Cr, hit by a $7 million US settlement and restructuring at its innovation arm, IGI. Operational tweaks include shutting down a manufacturing facility and moving production to a contract manufacturer. Despite setbacks, cash flow from operations stayed positive. Glenmark also proposed a final dividend of 250% (₹2.50/share), subject to shareholder approval.